Tumour-infiltrating Gr-1+ myeloid cells antagonize senescence in cancer
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
Aberrant activation of oncogenes or loss of tumour suppressor genes opposes malignant transformation by triggering a stable arrest in cell growth, which is termed cellular senescence. This process is finely tuned by both cell-autonomous and non-cell-autonomous mechanisms that regulate the entry of tumour cells to senescence. Whether tumour-infiltrating immune cells can oppose senescence is unknown. Here we show that at the onset of senescence, PTEN null prostate tumours in mice are massively infiltrated by a population of CD11b(+)Gr-1(+) myeloid cells that protect a fraction of proliferating tumour cells from senescence, thus sustaining tumour growth. Mechanistically, we found that Gr-1(+) cells antagonize senescence in a paracrine manner by interfering with the senescence-associated secretory phenotype of the tumour through the secretion of interleukin-1 receptor antagonist (IL-1RA). Strikingly, Pten-loss-induced cellular senescence was enhanced in vivo when Il1ra knockout myeloid cells were adoptively transferred to PTEN null mice. Therapeutically, docetaxel-induced senescence and efficacy were higher in PTEN null tumours when the percentage of tumour-infiltrating CD11b(+)Gr-1(+) myeloid cells was reduced using an antagonist of CXC chemokine receptor 2 (CXCR2). Taken together, our findings identify a novel non-cell-autonomous network, established by innate immunity, that controls senescence evasion and chemoresistance. Targeting this network provides novel opportunities for…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“By contrast, during cancer development associated with accumulation of senescent cells, SASP can recruit immature myeloid cells to promote tumorigenesis in a paracrine manner160,161.”
From Cellular senescence in ageing: from mechanisms to therapeutic opportunities (2021) · cites this paper as [160]
In the citing paper
“Further, the SASP can recruit immature immune-suppressive myeloid cells to prostate and liver tumors (Di Mitri et al., 2014; Eggert et al., 2016) and stimulate tumorigenesis by driving angiogenesis and metastasis (Coppe ´ et al., 2010).”
From Cellular Senescence: Defining a Path Forward (2019) · cites this paper as Di Mitri et al., 2014
In the citing paper
“In some instances, the SASP can also have immunosuppressive functions (Di Mitri et al. 2014; Eggert et al. 2016).”
From Senescence and the SASP: many therapeutic avenues (2020) · cites this paper as Di Mitri et al. 2014
In the citing paper
“Notably, data from various mouse models indicate that disrupting the CXCR1/2–MDSC axis in tumours is therapeutically efficacious across a wide variety of solid cancers166–172.”
From The current state of the art and future trends in RAS-targeted cancer therapies (2022) · cites this paper as [167]
In the citing paper
“There is convergent evidence that this occurs via the recruitment of myeloid-derived suppressor cells (MDSCs) chemoattracted by factors (e.g., IL-6, IL-8, and CCL2) secreted by senescent cells in murine models of HCC, 193 prostate, 194 and skin cancers.195”
From Meta-hallmarks of aging and cancer (2023) · cites this paper as [194]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
The cancer genome atlas pan-cancer analysis project
The Cancer Genome Atlas Research Network, Weinstein, J. N., Collisson, E. A., Mills, G. B., Shaw, K. R. M., Ozenberger, B. A., Ellrott, K., Shmulevich, I., Sander, C., & Stuart, J. M. (2013) · Nature Genetics · doi:10.1038/ng.2764 · Cited by 9,092
Myeloid-derived-suppressor cells as regulators of the immune system
Gabrilovich, D. I., & Nagaraj, S. (2009) · Nature Reviews Immunology · doi:10.1038/nri2506 · Cited by 6,753
Coordinated regulation of myeloid cells by tumours
Gabrilovich, D. I., Ostrand-Rosenberg, S., & Bronte, V. (2012) · Nature Reviews Immunology · doi:10.1038/nri3175 · Cited by 3,544
Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas
Xue, W., Zender, L., Miething, C., Dickins, R. A., Hernando, E., Krizhanovsky, V., Cordon-Cardo, C., & Lowe, S. W. (2007) · Nature · doi:10.1038/nature05529 · Cited by 2,473
A complex secretory program orchestrated by the inflammasome controls paracrine senescence
Acosta, J. C., Banito, A., Wuestefeld, T., Georgilis, A., Janich, P., Morton, J. P., Athineos, D., Kang, T.-W., Lasitschka, F., Andrulis, M., et al. (2013) · Nature Cell Biology · doi:10.1038/ncb2784 · Cited by 2,278
Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis
Chen, Z., Trotman, L. C., Shaffer, D., Lin, H.-K., Dotan, Z. A., Niki, M., Koutcher, J. A., Scher, H. I., Ludwig, T., Gerald, W., et al. (2005) · Nature · doi:10.1038/nature03918 · Cited by 1,993
Senescence surveillance of pre-malignant hepatocytes limits liver cancer development
Kang, T.-W., Yevsa, T., Woller, N., Hoenicke, L., Wuestefeld, T., Dauch, D., Hohmeyer, A., Gereke, M., Rudalska, R., Potapova, A., et al. (2011) · Nature · doi:10.1038/nature10599 · Cited by 1,621
Senescence in premalignant tumours
Collado, M., Gil, J., Efeyan, A., Guerra, C., Schuhmacher, A. J., Barradas, M., Benguría, A., Zaballos, A., Flores, J. M., Barbacid, M., et al. (2005) · Nature · doi:10.1038/436642a · Cited by 1,482
Self-citationOncogene-induced senescence as an initial barrier in lymphoma development
Braig, M., Lee, S., Loddenkemper, C., Rudolph, C., Peters, A. H. F. M., Schlegelberger, B., Stein, H., Dörken, B., Jenuwein, T., & Schmitt, C. A. (2005) · Nature · doi:10.1038/nature03841 · Cited by 1,220
Senescence in tumours: evidence from mice and humans
Collado, M., & Serrano, M. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2772 · Cited by 1,124
Self-citation
Cited by
Cellular Senescence: Defining a Path Forward
Gorgoulis, V., Adams, P. D., Alimonti, A., Bennett, D. C., Bischof, O., Bishop, C., Campisi, J., Collado, M., Evangelou, K., Ferbeyre, G., et al. (2019) · Cell · doi:10.1016/j.cell.2019.10.005 · Cited by 3,225
Self-citationCellular senescence in ageing: from mechanisms to therapeutic opportunities
Di Micco, R., Krizhanovsky, V., Baker, D., & d’Adda di Fagagna, F. (2021) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-020-00314-w · Cited by 2,277
Aging and aging-related diseases: from molecular mechanisms to interventions and treatments
Guo, J., Huang, X., Dou, L., Yan, M., Shen, T., Tang, W., & Li, J. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01251-0 · Cited by 1,718
Myeloid-Derived Suppressor Cells
Gabrilovich, D. I. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0297 · Cited by 1,882
“CD11bþGr1þ cells oppose cellular senescence in a model of spontaneous prostate cancer by antagonizing IL1a-mediated senescence (25).”
BackgroundNeutrophils in cancer: Neutral no more
Coffelt, S. B., Wellenstein, M. D., & de Visser, K. E. (2016) · Nature reviews. Cancer · doi:10.1038/nrc.2016.52 · Cited by 1,830
Mechanisms of Cellular Senescence: Cell Cycle Arrest and Senescence Associated Secretory Phenotype
Kumari, R., & Jat, P. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.645593 · Cited by 1,622
Cellular Senescence: Aging, Cancer, and Injury
Calcinotto, A., Kohli, J., Zagato, E., Pellegrini, L., Demaria, M., & Alimonti, A. (2019) · Physiological Reviews · doi:10.1152/physrev.00020.2018 · Cited by 1,270
Self-citationSenescence and aging: Causes, consequences, and therapeutic avenues
McHugh, D., & Gil, J. (2018) · Journal of Cell Biology · doi:10.1083/jcb.201708092 · Cited by 1,233
Mechanisms and functions of cellular senescence
Herranz, N., & Gil, J. (2018) · Journal of Clinical Investigation · doi:10.1172/jci95148 · Cited by 1,232
Senescence and the SASP: many therapeutic avenues
Birch, J., & Gil, J. (2020) · Genes & Development · doi:10.1101/gad.343129.120 · Cited by 1,177
“In some instances, the SASP can also have immunosuppressive functions (DiMitri et al. 2014; Eggert et al. 2016).”
BackgroundMyeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected
Marvel, D., & Gabrilovich, D. I. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80005 · Cited by 1,050
“CD11b + Gr1 + cells were also recently shown to oppose cellular senescence and promote a more aggressive disease in a mouse model of spontaneous prostate cancer by antagonizing IL-1 α –mediated senescence (52).”
BackgroundThe functions and regulation of the PTEN tumour suppressor: new modes and prospects
Lee, Y.-R., Chen, M., & Pandolfi, P. P. (2018) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-018-0015-0 · Cited by 917
Exploiting senescence for the treatment of cancer
Wang, L., Lankhorst, L., & Bernards, R. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-022-00450-9 · Cited by 867
Unmasking senescence: context-dependent effects of SASP in cancer
Faget, D. V., Ren, Q., & Stewart, S. A. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0156-2 · Cited by 863
Genetics and biology of prostate cancer
Wang, G., Zhao, D., Spring, D. J., & DePinho, R. A. (2018) · Genes & Development · doi:10.1101/gad.315739.118 · Cited by 750
“Gr1+ myeloid cells, which may include CD11b+Gr1+ MDSCs, have been shown to play a role in tumor progression and the evasion of PTEN loss-induced cellular senescence and chemoresistance in cancer cells in a mouse model of indolent Pten-null prostate cancer (Di Mitri et al. 2014; Garcia et al. 2014).”
BackgroundNeutrophils in cancer: heterogeneous and multifaceted
Hedrick, C. C., & Malanchi, I. (2022) · Nature Reviews Immunology · doi:10.1038/s41577-021-00571-6 · Cited by 768
The role of myeloid cells in cancer therapies
Engblom, C., Pfirschke, C., & Pittet, M. J. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.54 · Cited by 788
Chemokines and Chemokine Receptors: New Targets for Cancer Immunotherapy
Mollica Poeta, V., Massara, M., Capucetti, A., & Bonecchi, R. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00379 · Cited by 583
“Finally, in a prostate cancer model, CXCR2 inhibition by SB265610, decreased recruitment of myeloid cells and enhanced Docetaxel-induced senescence, limiting tumor growth (76).”
BackgroundCancer-Cell-Intrinsic Mechanisms Shaping the Tumor Immune Landscape
Wellenstein, M. D., & de Visser, K. E. (2018) · Immunity · doi:10.1016/j.immuni.2018.03.004 · Cited by 589
Ugel, S., De Sanctis, F., Mandruzzato, S., & Bronte, V. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80006 · Cited by 559
“At tumor onset in different autochthonous tumor models, neoplastic cells showed a senescent phenotype, a condition limiting tumor progression that was reversed by MDSCs (92).”
BackgroundTargeting YAP-Dependent MDSC Infiltration Impairs Tumor Progression
Wang, G., Lu, X., Dey, P., Deng, P., Wu, C. C., Jiang, S., Fang, Z., Zhao, K., Konaparthi, R., Hua, S., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0224 · Cited by 553
“MDSCs have been identified recently as a TME constituent in an indolent prostate cancer mouse model with conditional Pten deletion (9) and demonstrated to antagonize senescence during early tumorigenesis (10).”
The current state of the art and future trends in RAS-targeted cancer therapies
Punekar, S. R., Velcheti, V., Neel, B. G., & Wong, K.-K. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00671-9 · Cited by 549
Effective combinatorial immunotherapy for castration-resistant prostate cancer
Lu, X., Horner, J. W., Paul, E., Shang, X., Troncoso, P., Deng, P., Jiang, S., Chang, Q., Spring, D. J., Sharma, P., et al. (2017) · Nature · doi:10.1038/nature21676 · Cited by 547
Myeloid-Derived Suppressor Cells Hinder the Anti-Cancer Activity of Immune Checkpoint Inhibitors
Weber, R., Fleming, V., Hu, X., Nagibin, V., Groth, C., Altevogt, P., Utikal, J., & Umansky, V. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01310 · Cited by 538
Meta-hallmarks of aging and cancer
López-Otín, C., Pietrocola, F., Roiz-Valle, D., Galluzzi, L., & Kroemer, G. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2022.11.001 · Cited by 529
Senescent Cells in Cancer Therapy: Friends or Foes?
Wang, B., Kohli, J., & Demaria, M. (2020) · Trends in Cancer · doi:10.1016/j.trecan.2020.05.004 · Cited by 508
“Importantly, blocking myeloid cell recruitment via CXCR2 inhibition sensitizes prostate cancer cells to docetaxel-induced senescence [102].”
BackgroundMyeloid-Derived Suppressor Cells as a Therapeutic Target for Cancer
Law, A. M. K., Valdes-Mora, F., & Gallego-Ortega, D. (2020) · Cells · doi:10.3390/cells9030561 · Cited by 455
Alfaro, C., Teijeira, A., Oñate, C., Pérez, G., Sanmamed, M. F., Andueza, M. P., Alignani, D., Labiano, S., Azpilikueta, A., Rodriguez-Paulete, A., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2463 · Cited by 417
“Indeed, therapies that selectively damage such myeloid cell subsets exert therapeutic effects (18, 46) and are actively pursued in the clinical setting (47).”
BackgroundIl-23 secreted by myeloid cells drives castration-resistant prostate cancer
Calcinotto, A., Spataro, C., Zagato, E., Di Mitri, D., Gil, V., Crespo, M., De Bernardis, G., Losa, M., Mirenda, M., Pasquini, E., et al. (2018) · Nature · doi:10.1038/s41586-018-0266-0 · Cited by 394
Self-citationImmunosuppression associated with chronic inflammation in the tumor microenvironment
Wang, D., & DuBois, R. N. (2015) · Carcinogenesis · doi:10.1093/carcin/bgv123 · Cited by 355
“MDSCs directly enhanced cancer stem-like cell formation and protected proliferating tumor cells from senescence without involvement of T cells and NKs in vivo (70,71).”
BackgroundCXCL1 Is Critical for Premetastatic Niche Formation and Metastasis in Colorectal Cancer
Wang, D., Sun, H., Wei, J., Cen, B., & DuBois, R. N. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-3199 · Cited by 356
Neutrophils and PMN-MDSC: Their biological role and interaction with stromal cells
Zhou, J., Nefedova, Y., Lei, A., & Gabrilovich, D. (2018) · Seminars in Immunology · doi:10.1016/j.smim.2017.12.004 · Cited by 339
De Cicco, P., Ercolano, G., & Ianaro, A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01680 · Cited by 332
p53, cancer and the immune response
Blagih, J., Buck, M. D., & Vousden, K. H. (2020) · Journal of Cell Science · doi:10.1242/jcs.237453 · Cited by 333
“As a consequence, some tumour cells bypass proliferation arrest and progress to prostate cancer (Di Mitri et al., 2014).”
BackgroundEpigenetic therapy inhibits metastases by disrupting premetastatic niches
Lu, Z., Zou, J., Li, S., Topper, M. J., Tao, Y., Zhang, H., Jiao, X., Xie, W., Kong, X., Vaz, M., et al. (2020) · Nature · doi:10.1038/s41586-020-2054-x · Cited by 330
Monocytes in the Tumor Microenvironment
Ugel, S., Canè, S., De Sanctis, F., & Bronte, V. (2021) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-012418-013058 · Cited by 314
Tumor-associated neutrophils and neutrophil-targeted cancer therapies
Que, H., Fu, Q., Lan, T., Tian, X., & Wei, X. (2022) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2022.188762 · Cited by 312
Wang, L., Liu, Y., Dai, Y., Tang, X., Yin, T., Wang, C., Wang, T., Dong, L., Shi, M., Qin, J., et al. (2023) · Gut · doi:10.1136/gutjnl-2021-326070 · Cited by 306
Differential effects on lung and bone metastasis of breast cancer by Wnt signalling inhibitor DKK1
Zhuang, X., Zhang, H., Li, X., Li, X., Cong, M., Peng, F., Yu, J., Zhang, X., Yang, Q., & Hu, G. (2017) · Nature Cell Biology · doi:10.1038/ncb3613 · Cited by 309
Taki, M., Abiko, K., Baba, T., Hamanishi, J., Yamaguchi, K., Murakami, R., Yamanoi, K., Horikawa, N., Hosoe, Y., Nakamura, E., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03966-7 · Cited by 296
Therapy-Induced Senescence: An “Old” Friend Becomes the Enemy
Saleh, T., Bloukh, S., Carpenter, V. J., Alwohoush, E., Bakeer, J., Darwish, S., Azab, B., & Gewirtz, D. A. (2020) · Cancers · doi:10.3390/cancers12040822 · Cited by 290
Horikawa, N., Abiko, K., Matsumura, N., Hamanishi, J., Baba, T., Yamaguchi, K., Yoshioka, Y., Koshiyama, M., & Konishi, I. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0387 · Cited by 275
Peña-Romero, A. C., & Orenes-Piñero, E. (2022) · Cancers · doi:10.3390/cancers14071681 · Cited by 257
Melanocytic nevi and melanoma: unraveling a complex relationship
Damsky, W. E., & Bosenberg, M. (2017) · Oncogene · doi:10.1038/onc.2017.189 · Cited by 248
Biological Roles of Neutrophil-Derived Granule Proteins and Cytokines
Cassatella, M. A., Östberg, N. K., Tamassia, N., & Soehnlein, O. (2019) · Trends in Immunology · doi:10.1016/j.it.2019.05.003 · Cited by 249
Senescence Rewires Microenvironment Sensing to Facilitate Antitumor Immunity
Chen, H.-A., Ho, Y.-J., Mezzadra, R., Adrover, J. M., Smolkin, R., Zhu, C., Woess, K., Bernstein, N., Schmitt, G., Fong, L., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0528 · Cited by 230
Prostate carcinogenesis: inflammatory storms
de Bono, J. S., Guo, C., Gurel, B., De Marzo, A. M., Sfanos, K. S., Mani, R. S., Gil, J., Drake, C. G., & Alimonti, A. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-020-0267-9 · Cited by 227
Self-citationCellular senescence: Immunosurveillance and future immunotherapy
Burton, D. G. A., & Stolzing, A. (2018) · Ageing Research Reviews · doi:10.1016/j.arr.2018.02.001 · Cited by 221
“…a study conducted by Di Mitri et al demonstrated that senescence induction in PTEN null prostate tumours in mice promoted an infiltration of Gr-1+ myeloid cells which protected a fraction of proliferating tumour cells from cell senescence, thereby sustaining tumour growth (Di Mitri et al., 2014).”
BackgroundEmerging role of PTEN loss in evasion of the immune response to tumours
Vidotto, T., Melo, C. M., Castelli, E., Koti, M., dos Reis, R. B., & Squire, J. A. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-0834-6 · Cited by 209
“MDSCs are also thought to sustain tumour growth by protecting proliferating tumour cells from senescence.(100) Owing to the ability of MDSCs to modulate the antitumour immune response, the Table 2.”
BackgroundTreffers, L. W., Hiemstra, I. H., Kuijpers, T. W., van den Berg, T. K., & Matlung, H. L. (2016) · Immunological Reviews · doi:10.1111/imr.12444 · Cited by 197
“First results of the use of small-molecule antagonists of CXCR1 and CXCR2 indeed showed anti-tumor effects in xenograft models of breast cancer (30) and also in PTEN / prostate tumors in mice, in which a significant reduction in GR1 cells resulted in enhanced docetaxel-induced tumor suppression (31).”
BackgroundSASP: Tumor Suppressor or Promoter? Yes!
Rao, S. G., & Jackson, J. G. (2016) · Trends in Cancer · doi:10.1016/j.trecan.2016.10.001 · Cited by 206
In Vitro and in Vivo Mechanism of Bone Tumor Inhibition by Selenium-Doped Bone Mineral Nanoparticles
Wang, Y., Wang, J., Hao, H., Cai, M., Wang, S., Ma, J., Li, Y., Mao, C., & Zhang, S. (2016) · ACS Nano · doi:10.1021/acsnano.6b03835 · Cited by 206
Chemokine-Directed Tumor Microenvironment Modulation in Cancer Immunotherapy
Bule, P., Aguiar, S. I., Aires-Da-Silva, F., & Dias, J. N. R. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22189804 · Cited by 185
Spleen mediates a distinct hematopoietic progenitor response supporting tumor-promoting myelopoiesis
Wu, C., Ning, H., Liu, M., Lin, J., Luo, S., Zhu, W., Xu, J., Wu, W.-C., Liang, J., Shao, C.-K., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci97973 · Cited by 193
Lorente, D., Mateo, J., Templeton, A. J., Zafeiriou, Z., Bianchini, D., Ferraldeschi, R., Bahl, A., Shen, L., Su, Z., Sartor, O., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdu587 · Cited by 192
“On the other hand, the presence of intra-tumoral Gr1+ myeloid precursors has been reported to protect PTEN null prostate transgenic cells from chemotherapy-induced senescence [17], fuelling their proliferation; whether a high relative neutrophil count reflects such an increase in myeloid infiltration of tumour tissue…”
BackgroundSenescence as a therapeutic target in cancer and age-related diseases
McHugh, D., Durán, I., & Gil, J. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-01074-4 · Cited by 197
“For example, in established tumours, the SASP can recruit MDSCs that promote an immune suppressive TME 45,46 .”
InfluentialSenescent Cells: Emerging Targets for Human Aging and Age-Related Diseases
Song, S., Lam, E. W.-F., Tchkonia, T., Kirkland, J. L., & Sun, Y. (2020) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2020.03.008 · Cited by 195
Neutrophils in Cancer immunotherapy: friends or foes?
Huang, X., Nepovimova, E., Adam, V., Sivak, L., Heger, Z., Valko, M., Wu, Q., & Kuca, K. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02004-z · Cited by 172
“This antagonistic senescence response is attributed to the release of interleukin-1 receptor antagonist (IL-1RA) by neutrophils [60] (see Fig.”
BackgroundSaleh, T., Carpenter, V. J., Tyutyunyk‐Massey, L., Murray, G., Leverson, J. D., Souers, A. J., Alotaibi, M. R., Faber, A. C., Reed, J., Harada, H., et al. (2020) · Molecular Oncology · doi:10.1002/1878-0261.12761 · Cited by 190
Cellular senescence and the tumour microenvironment
Takasugi, M., Yoshida, Y., & Ohtani, N. (2022) · Molecular Oncology · doi:10.1002/1878-0261.13268 · Cited by 172
Apolipoprotein E induces pathogenic senescent-like myeloid cells in prostate cancer
Bancaro, N., Calì, B., Troiani, M., Elia, A. R., Arzola, R. A., Attanasio, G., Lai, P., Crespo, M., Gurel, B., Pereira, R., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.02.004 · Cited by 177
Self-citationImmune Infiltration and Prostate Cancer
Strasner, A., & Karin, M. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00128 · Cited by 184
“DiMitri (59) Positive: massive infiltration of Gr1CD11b cells at onset of senescence induced by complete PTEN loss (with or without Docetaxel).”
BackgroundSenescence Reprogramming by TIMP1 Deficiency Promotes Prostate Cancer Metastasis
Guccini, I., Revandkar, A., D'Ambrosio, M., Colucci, M., Pasquini, E., Mosole, S., Troiani, M., Brina, D., Sheibani-Tezerji, R., Elia, A. R., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.10.012 · Cited by 185
Self-citationNeutrophil Heterogeneity in Cancer: From Biology to Therapies
Lecot, P., Sarabi, M., Pereira Abrantes, M., Mussard, J., Koenderman, L., Caux, C., Bendriss-Vermare, N., & Michallet, M.-C. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02155 · Cited by 171
Diverse genetic-driven immune landscapes dictate tumor progression through distinct mechanisms
Bezzi, M., Seitzer, N., Ishikawa, T., Reschke, M., Chen, M., Wang, G., Mitchell, C., Ng, C., Katon, J., Lunardi, A., et al. (2018) · Nature Medicine · doi:10.1038/nm.4463 · Cited by 172
Lai, P., Liu, L., Bancaro, N., Troiani, M., Calì, B., Li, Y., Chen, J., Singh, P. K., Arzola, R. A., Attanasio, G., et al. (2025) · Immunity · doi:10.1016/j.immuni.2025.03.005 · Cited by 174
Self-citationSalvagno, C., Ciampricotti, M., Tuit, S., Hau, C.-S., van Weverwijk, A., Coffelt, S. B., Kersten, K., Vrijland, K., Kos, K., Ulas, T., et al. (2019) · Nature Cell Biology · doi:10.1038/s41556-019-0298-1 · Cited by 168
Ly6Clo monocytes drive immunosuppression and confer resistance to anti-VEGFR2 cancer therapy
Jung, K., Heishi, T., Khan, O. F., Kowalski, P. S., Incio, J., Rahbari, N. N., Chung, E., Clark, J. W., Willett, C. G., Luster, A. D., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci93182 · Cited by 164
Immunomodulation by anticancer cell cycle inhibitors
Petroni, G., Formenti, S. C., Chen-Kiang, S., & Galluzzi, L. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0300-y · Cited by 163
Role of prostanoids in gastrointestinal cancer
Wang, D., & DuBois, R. N. (2018) · Journal of Clinical Investigation · doi:10.1172/jci97953 · Cited by 158
Preclinical murine tumor models: A structural and functional perspective
Guérin, M. V., Finisguerra, V., den Eynde, B. J. V., Bercovici, N., & Trautmann, A. (2020) · eLife · doi:10.7554/elife.50740 · Cited by 165
“…of immunosuppressive myeloid-derived suppressor cells (MDSCs) (Sevko et al., 2013; Coffelt and de Visser, 2015), amongst which neutrophils often play an important pro-tumoral role, both in primary tumors (Di Mitri et al., 2014; Zhu et al., 2017) and in metastases (Coffelt and de Visser, 2015).”
BackgroundThe multifaceted role of the SASP in atherosclerosis: from mechanisms to therapeutic opportunities
Sun, Y., Wang, X., Liu, T., Zhu, X., & Pan, X. (2022) · Cell & Bioscience · doi:10.1186/s13578-022-00815-5 · Cited by 168
IL-1 family cytokines in inflammation and immunity
Garlanda, C., Ceglie, I. D., & Jaillon, S. (2025) · Cellular and Molecular Immunology · doi:10.1038/s41423-025-01358-8 · Cited by 168
“Additionally, neutrophils express IL-1Ra and the decoy receptor IL-1R2, which limits in fl ammatory responses and interferes with the senescence-associated secretory phenotype [63, 128].”
Wu, Z., Trevino, A. E., Wu, E., Swanson, K., Kim, H. J., D’Angio, H. B., Preska, R., Charville, G. W., Dalerba, P. D., Egloff, A. M., et al. (2022) · Nature Biomedical Engineering · doi:10.1038/s41551-022-00951-w · Cited by 154
The innate immune sensor Toll-like receptor 2 controls the senescence-associated secretory phenotype
Hari, P., Millar, F. R., Tarrats, N., Birch, J., Quintanilla, A., Rink, C. J., Fernández-Duran, I., Muir, M., Finch, A. J., Brunton, V. G., et al. (2019) · Science Advances · doi:10.1126/sciadv.aaw0254 · Cited by 154
Targeting myeloid chemotaxis to reverse prostate cancer therapy resistance
Guo, C. W., Sharp, A., Gürel, B., Crespo, M., Figueiredo, I., Jain, S., Vogl, U. M., Rekowski, J., Rouhifard, M., Gallagher, L., et al. (2023) · Nature · doi:10.1038/s41586-023-06696-z · Cited by 160
“In models of different tumours, including prostate cancer, CXCR2 inhibition blocks the recruitment of tumour-infiltrating PMN-MDSCs leading to tumour suppression 10,12,14,24,25 .”
BackgroundInfluentialSelf-citationHou, A., Hou, K., Huang, Q., Lei, Y., & Chen, W. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00783 · Cited by 145
“It seems that the functional, biochemical and genomic characterization of PMN-MDSCs described in many studies is conducted for the entire population of cells, not for PMN-MDSCs only.”
BackgroundInfluentialImmune-mediated mechanisms influencing the efficacy of anticancer therapies
Coffelt, S. B., & de Visser, K. E. (2015) · Trends in Immunology · doi:10.1016/j.it.2015.02.006 · Cited by 162
“Similarly, docetaxel synergizes with a CXCR2 inhibitor to prevent tumor progression in a GEMM for Ptendeficient prostate cancer [45].”
BackgroundCabozantinib Eradicates Advanced Murine Prostate Cancer by Activating Antitumor Innate Immunity
Patnaik, A., Swanson, K. D., Csizmadia, E., Solanki, A., Landon-Brace, N., Gehring, M. P., Helenius, K., Olson, B. M., Pyzer, A. R., Wang, L. C., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0778 · Cited by 146
Senescence and the tumor-immune landscape: Implications for cancer immunotherapy
Chibaya, L., Snyder, J. T., & Ruscetti, M. A. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.02.005 · Cited by 161
Colucci, M., Sarill, M., Maddalena, M., Valdata, A., Troiani, M., Massarotti, M., Bolis, M., Bressan, S., Kohl, A., Robesti, D., et al. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.05.015 · Cited by 164
Self-citationDrug discovery in advanced prostate cancer: translating biology into therapy
Yap, T. A., Smith, A. D., Ferraldeschi, R., Al‐Lazikani, B., Workman, P., & Bono, J. S. D. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.120 · Cited by 157
Takeuchi, S., Baghdadi, M., Tsuchikawa, T., Wada, H., Nakamura, T., Abe, H., Nakanishi, S., Usui, Y., Higuchi, K., Takahashi, M., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-2921 · Cited by 138
Voigt, C., May, P., Gottschlich, A., Markota, A., Wenk, D., Gerlach, I., Voigt, S., Stathopoulos, G. T., Arendt, K. A. M., Heise, C., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1705165114 · Cited by 141
“IL-1α is mostly cell-associated in viable cells but may be released from dying tumor cells (30, 31).”
BackgroundSingle-cell transcriptomics identifies Mcl-1 as a target for senolytic therapy in cancer
Troiani, M., Colucci, M., D’Ambrosio, M., Guccini, I., Pasquini, E., Varesi, A., Valdata, A., Mosole, S., Revandkar, A., Attanasio, G., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-29824-1 · Cited by 123
“Senescent tumor cells are known to be resistant to programmed cell death due to the upregulation of BCL2 and BCL-XL 1,2,46,47 .”
Self-citationNeutrophil dynamics in the tumor microenvironment
McFarlane, A. J., Fercoq, F., Coffelt, S. B., & Carlin, L. M. (2021) · Journal of Clinical Investigation · doi:10.1172/jci143759 · Cited by 138
Chesney, J. A., Mitchell, R. A., & Yaddanapudi, K. (2017) · Journal of Leukocyte Biology · doi:10.1189/jlb.5vmr1116-458rrr · Cited by 124
“prostate lesions of Pten-null mice, eventually promoting tumor progression [108].”
BackgroundSerresi, M., Gargiulo, G., Proost, N., Siteur, B., Cesaroni, M., Koppens, M. A. J., Xie, H., Sutherland, K. D., Hulsman, D., Citterio, E., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2015.12.006 · Cited by 128
“This warrants investigation on possible microenvironment-regulated anti-tumor responses (Di Mitri et al., 2014).”
BackgroundResultMacrophage-Derived Cholesterol Contributes to Therapeutic Resistance in Prostate Cancer
El-Kenawi, A., Dominguez-Viqueira, W., Liu, M., Awasthi, S., Abraham-Miranda, J., Keske, A., Steiner, K. K., Noel, L., Serna, A. N., Dhillon, J., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-4028 · Cited by 113
Qi, Z., Xu, Z., Zhang, L., Zou, Y., Li, J., Yan, W., Li, C., Liu, N., & Wu, H. (2022) · Nature Communications · doi:10.1038/s41467-021-27833-0 · Cited by 137
Li, N., Liu, Q., Han, Y., Pei, S., Cheng, B., Xu, J., Miao, X., Pan‐Hammarström, Q., Wang, H., Guo, J., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34871-9 · Cited by 123
Oncogene-induced senescence: From biology to therapy
Zhu, H., Blake, S., Kusuma, F. K., Pearson, R. B., Kang, J., & Chan, K. T. (2020) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2020.111229 · Cited by 116
Targeting senescence as an anticancer therapy
Bousset, L., & Gil, J. (2022) · Molecular Oncology · doi:10.1002/1878-0261.13312 · Cited by 123
Reshaping of the tumor microenvironment by cellular senescence: An opportunity for senotherapies
D’Ambrosio, M., & Gil, J. (2023) · Developmental Cell · doi:10.1016/j.devcel.2023.05.010 · Cited by 119
Paramos-de-Carvalho, D., Jacinto, A., & Saúde, L. (2021) · eLife · doi:10.7554/elife.72449 · Cited by 111
Autophagy and senescence in cancer therapy
Gewirtz, D. A. (2013) · Journal of Cellular Physiology · doi:10.1002/jcp.24420 · Cited by 107
Stromal Senescence By Prolonged CDK4/6 Inhibition Potentiates Tumor Growth
Guan, X., LaPak, K. M., Hennessey, R. C., Yu, C. Y., Shakya, R., Zhang, J., & Burd, C. E. (2016) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-16-0319 · Cited by 115
“Here, the onset of senescence inmurineprostate tumors promotes the accumulation of Gr-1–positive cells, leading to reduced antitumor immunity and enhanced cancer growth (39).”
BackgroundTo clear, or not to clear (senescent cells)? That is the question
Lujambio, A. (2016) · BioEssays · doi:10.1002/bies.201670910 · Cited by 108
MDSCs in cancer: Conceiving new prognostic and therapeutic targets
Sanctis, F. D., Solito, S., Ugel, S., Molon, B., Bronte, V., & Marigo, I. (2015) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2015.08.001 · Cited by 111
“the conditional oncosuppressor PTEN prostate adenocarcinoma and oncogenemediated Ki-ras lung adenocarcinoma [129].”
BackgroundIL-1 Signaling in Tumor Microenvironment
Zhang, W., Borcherding, N. C., & Kolb, R. H. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-38315-2_1 · Cited by 107
Metadata
- Authors
- Di Mitri, D., Toso, A., Chen, J. J., Sarti, M., Pinton, S., Jost, T. R., D’Antuono, R., Montani, E., Garcia-Escudero, R., Guccini, I., Da Silva-Alvarez, S., Collado, M., Eisenberger, M., Zhang, Z., Catapano, C., Grassi, F., & Alimonti, A.
- Affiliations
- Institute of Oncology Research (CH)
- Institute for Research in Biomedicine (CH)
- Complejo Hospitalario Universitario de Santiago (ES)
- Johns Hopkins University (US)
- University of Milan (IT)
- Corresponding author
- Alimonti, Andrea
- ORCID
- Venue
- Nature
- Published
- 2014-08-24
- Volume
- 515
- Issue
- 7525
- Pages
- 134-137
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W1968545383
- Cited by
- 388
- References
- 32
- Citations by year
- 2026: 25 · 2025: 41 · 2024: 31 · 2023: 39 · 2022: 35 · 2021: 32 · 2020: 44 · 2019: 22 · 2018: 33 · 2017: 30 · 2016: 26 · 2015: 23 · 2014: 3
- FWCI
- 18.22
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- other-oa
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- IRIS (submittedVersion)
- RUNA. Repositorio Institucional del Sergas (Servicio Gallego de Salud (SERGAS)) (submittedVersion, other-oa)
- SERVAL (Université de Lausanne) (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Aging › Genetics, Aging, and Longevity in Model Organisms
- Keywords
- cellular senescence, senescence evasion, interleukin-1 receptor antagonist, senescence-associated secretory phenotype, chemoresistance, docetaxel, CXCR2 antagonist, innate immunity, tumor microenvironment
- MeSH terms
- Docetaxel, Animals, Cell Movement, Humans, Immunity, Innate, Male, Prostatic Neoplasms, Cellular Senescence, Disease Progression, Drug Resistance, Neoplasm, Tumor Escape, Receptors, Chemokine, Myeloid Cells, Receptors, Interleukin-8B, Taxoids, PTEN Phosphohydrolase, Mice, Interleukin-1alpha, Interleukin 1 Receptor Antagonist Protein, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.